Swedish MedTech company Mölnlycke Health Care has begun construction of its first wound care manufacturing site in China, marking a new milestone in the company’s expansion across Asia.
The new 10,000-square-metre facility in Changshu will produce Mölnlycke’s wound care products locally, with operations expected to begin by late 2026 or early 2027. The investment supports the company’s strategy to manufacture closer to its customers and strengthen supply chain resilience in one of the world’s fastest-growing healthcare markets.
“Our site in Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance,” says Zlatko Rihter, CEO of Mölnlycke.
The new site will be established according to Mölnlycke’s global quality standards and will create new local employment opportunities.
“This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, high-quality solutions,” adds Jakob Sonnenberg, VP Greater China & India Wound Care at Mölnlycke.
Founded in 1849 and headquartered in Gothenburg, Mölnlycke is a leading global provider of wound care and surgical solutions, with products used daily in over 100 countries. The company is owned by Investor AB.
Source: The Laotian Times
